Web Only - Pharmaceutical Executive

Web Only

Stories, articles, and news items that appear only on the Pharm Exec Web site.

What's the best managed pharma company? Find out in the Industry Audit and Company of the Year Podcast

October 21, 2009

Industry Audit and Company of The year.

Grim Outlook For UK Biotech Industry

March 11, 2009
By:Sarah Houlton

It could be the end of the road for the UK's biotech firms if drastic action isn't taken soon.

Wyeth V. Levine: An Attorneys' Perspective

March 11, 2009
By:Paul da Costa, Sharon Caffrey, Alan Klein

Lawyers from Duane Morris LLP offer their take on the Supreme Court's groundshaking preemption decision

Capitalizing on Strategic Market Insight

March 2, 2009
By:Mark T. Morgan, Rita Numerof

To stay on top of a constantly evolving market that presents new challenges every day, product managers need to bolster branding strategies and raise their marketing IQ.

Vytorin Down, Crestor Up

April 16, 2008
By:George Koroneos, Online Content & News Editor

Analysts predicted that Vytorin might recover quickly from the effects of its ENHANCE trial. A new survey from Deutsche Bank says the pain will continue.

Takeda Picks Up Millennium

April 16, 2008
By:George Koroneos, Online Content & News Editor

Japanese drugmaker buys the cancer-specialist biotech for a whopping $8.8 billion.

Docs Give As for E-promos

April 9, 2008
By:George Koroneos, Online Content & News Editor

GSK and Merck won high marks from physicians for their electronic promotions, according to a new study. But do docs really want to skip the live sales calls and go online for info?

DTC Ads to Solicit Side Effects Data?

April 9, 2008
By:George Koroneos, Online Content & News Editor

Spurred by a Consumer Reports poll, lawmakers are pushing FDA to place its phone number on every pharma ad to encourage consumers to report adverse drug reactions.

ESA Restrictions Leave Many Questions Unanswered

March 19, 2008
By:George Koroneos, Online Content & News Editor

Safety recommendations for erythropoiesis-stimulating agents have been released, but a lack of data and a narrow list of indication restrictions have left patient advocacy groups worried about unknown adverse effects.